Adhesion molecules and stromal cell-derived factor-1 (SDF-1)/ CXCR4 signaling play key role in homing and mobilization of hematopoietic progenitor (HPC) and hematopoietic cancer clonogenic cells (HCC). High expression of VLA-4 is required for homing of HPC and HCC, whereas downregulation of these molecules is required for successful mobilization of HPC and HCC. Upregulation and activation of the SDF-1/CXCR4 signaling is required for homing of HPC and HCC, whereas disruption of the SDF-1 signaling is required for mobilization of HPC and HCC. Hence, mobilizations of HPC and HCC occur concurrently. It is proposed that drug resistance evolves as a result of repeated cycles of chemotherapy. Following each cycle of chemotherapy, HCC lose adhesion molecules and SDF-1 signaling. Surviving cells, released from tumor sites, circulate until re-expression of adhesion molecules and CXCR4 occurs, then homing to stroma of distal tissues occurs. Cytokines secreted by cells in the new microenvironment induce proliferation and drug resistance of HCC. This process is amplified in each cycle of chemotherapy resulting in disease progression. A novel model for treatment is proposed in which circulating HCC are the target for clinical intervention, and concurrent treatment with chemotherapy and antilineage-specific antibodies will result in abrogation of the 'vicious cycle' of conventional anticancer therapy.
Mobilization of hematopoietic stem cells
Mobilization of hematopoietic progenitor cells (HPC), defined here as CD34 þ /CD45À cells can be achieved by the administration of chemotherapy, by hematopoietic growth factors such as G-CSF or GM-CSF (autologous and allogeneic donors), or by chemotherapy plus hematopoietic growth factor (autologous donors). In the latter case, higher yields of CD34 þ cells are usually obtained.
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Adhesion molecules in homing and mobilization of HPC Numerous studies have been reported on the involvement of adhesion molecules in the process of mobilization of CD34 þ cells. Among the most studied molecules are CD49d (VLA-4); CD49e (VLA-5) and its receptor, vascular adhesion molecule-1 (VCAM-1);
20-41 LFA-1 (CD18/CD11a) and its receptor, intracellular adhesion molecule-1 (I-CAM); and CD62L (L-selectin) and its receptor on endothelial cells. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [42] [43] [44] [45] In particular VLA-4, VLA-5 and L-selectin were found to be downregulated in mobilized peripheral blood compared to steady-state bone marrow (BM) CD34 þ cells. [20] [21] [22] [23] [24] [25] [32] [33] [34] [35] [42] [43] [44] [45] Direct evidence for the involvement of VLA-4 and VCAM-1 in the release of CD34 þ cells to the peripheral blood was derived from the finding that treatment of mice with antibodies to VLA-4 and VCAM-1 [26] [27] [28] [29] [30] results in HPC mobilization to the peripheral blood. Of note is the pioneering work in this field of Papayannoulou's group in which antibodies to VLA-4 were successfully used to induce mobilization of HPC in mice. 29, 30 Subsequently, they showed that anti-VLA-4 antibody acts synergistically with G-CSF to induce peripheral blood stem cell (PBSC) mobilization in various animal models. 31 Other adhesion molecules such as selectins and H-CAM (CD44) were also reported to play a role in mobilization of HPC. [32] [33] [34] [35] [36] Antibodies to CD44 were also capable of mobilizing CD34 þ cells in mice. 37 A detailed review of stem cell mobilization is avialable in the literature. [38] [39] [40] [41] [46] [47] [48] [49] [50] [51] SDF-1 and CXCR4 signaling in homing and mobilization of HPC CXCR4 is the receptor for the chemokine stromal cell-derived factor-1 (SDF-1). CXCR4 is expressed on lymphocytes, myeloid cells, megakaryocytes and CD34 þ cells enabling these cells to migrate across a gradient of SDF-1 concentrations. [52] [53] [54] [55] [56] [57] [58] SDF-1 is a survival and a proliferation factor for CD34 þ cells. [58] [59] [60] Mice reconstituted with BM derived from SDF-1-deficient donor mice exhibited impaired lymphopoiesis. 61 In several publications, Lapidot's group reported the involvement of adhesion molecules, the chemokine SDF-1 and CXCR4 in the process of homing of human CD34 þ cells in a NOD/SCID xenograft mouse model. Their data established a system of intricate signaling between adhesion molecules and chemokines in this model. [62] [63] [64] [65] This group has also shown that high concentrations of SDF-1 can downregulate the expression of CXCR4 in vitro and in vivo in a feedback mechanism. 62 On the other hand, Lapidot's group and others have shown that SDF-1 can activate adhesion molecules such as VLA-4 and LAF-1 and in this way plays an important role in homing and engraftment. [63] [64] [65] [66] [67] Similarly, Sweeney and co-workers have shown the involvement of SDF-1 in HPC mobilization using sulfated glycans to manipulate the levels of SDF-1. 68, 69 Also, recent studies by Petit et al 52 and Lapidot and Petit 50 confirmed the roles of SDF-1 and CXCR4 in human HPC mobilization in the NOD/SCID mouse model. Although there is a wide consensus regarding the role of SDF-1 and CXCR4 in homing and engraftment, others reported that treatment with anti-CXCR4 antibodies or with SDF-1 results in enhanced migration in vitro and increased homing in vivo. [70] [71] [72] [73] A number of recent publications demonstrate an active role for SDF-1 and CXCR4 in hematopoietic stem cell release from the BM to the circulation. Studies in our laboratory reported a decrease in the expression of CXCR4 on CD34 þ cells in PBSC apheresis collections of non-Hodgkin's lymphoma (NHL) patients mobilized with cyclophosphamide plus G-CSF or GM-CSF compared to steady-state BM. 74 Furthermore, it was shown that 'good mobilizers' had statistically lower percentages of CD34 þ CXCR4 þ cells compared to the pool of the 'poor mobilizers'. 74 We also reported a statistically significant decrease in the levels of plasma SDF-1 in the apheresis collections compared to the premobilization BM or peripheral blood. Furthermore, we reported that plasma SDF-1 levels in PBSC collections derived from 'good mobilizers' were statistically significantly lower than plasma SDF-1 levels in PBSC collection of 'poor mobilizers' group of patients. 74 Thus, desensitization of the SDF-1 CXCR4 signaling pathway is required for successful CD34 þ cell release from the BM to the peripheral blood and can predict for good mobilization. Supporting the crucial role of CXCR4/SDF-1 signaling in the mobilization of HPC are recent reports demonstrating that blocking of CXCR4 results in mobilization of CD34 þ HPC.
CXCR4-blocking molecules were recently developed to block the entry of T-lymphotropic HIV into T cells. [75] [76] [77] [78] [79] [80] [81] These peptidomimetic molecules are very specific CXCR4 blockers and are effective inducers of HPC mobilization in animal models and in humans. [80] [81] [82] [83] One of these molecules, AMD3100, was tested recently for its ability to mobilize HPC in humans. Thus, in a phase I-II clinical trial, a single injection of AMD3100 resulted in CD34 þ cell mobilization comparable to 5 days treatment with 10 mg/kg of G-CSF. Furthermore, AMD3100 synergized with G-CSF in the mobilization of primitive CD34 þ HPC with self-renewal and competitive repopulating potential. 82, 83 Proteases involved in the mobilization of HPC Recent reports suggest that neutrophil elastase and cathepsin G are the primary proteases involved in the release of HPC to the circulation in mice, monkeys and in humans. [84] [85] [86] [87] [88] Elastase plays a major role in dislodging HPC from BM stroma by degrading VLA-4 and VCAM. These proteases also degrade CXCR4 and SDF-1 in vitro and in vivo at the amino-terminal residue of both molecules. [84] [85] [86] [87] [88] Degradation of CXCR4 and SDF-1 could be demonstrated by pure elastase or by plasma from mobilized PBSC. 78, 80, 81 Of particular interest is a recent report by Levesque et al [85] [86] [87] indicating that both neutrophil elastase and cathepsin G can abrogate the binding of anti-CXCR4 antibody (clone 6H8) to the NALM6, pre-B leukemia cells and to normal CD34 þ cells, isolated from BM with no apparent decrease in the binding of the 12G5 monoclonal anti-CXCR4 antibody, which binds to a different epitop. Most importantly, the very same N-terminus epitop of the CXCR4 molecule was missing in CD34 þ HPC, isolated from G-CSF mobilized donors, where a similar cleavage occurred in vivo, resulting in an impaired response of these cells to exogenous SDF-1 in an in vitro chemotaxis assay. 86, 88 Hence, neutrophil elastase may contribute directly to desensitization of the CXCR4/SDF-1 signaling pathway and to the release of HPC from the BM. Other proteases, such as MMP9, 89 and the cell surface peptidase (CD26) on HPC 90 have also been implicated in HPC mobilization. However, additional studies are needed to evaluate the clinical relevance of these observations.
In a detailed study of eight normal donors, we compared the kinetics of downregulation of CXCR4 and SDF-1 in the blood of G-CSF mobilized donors, relative to the increase in plasma elastase activity. We found similar kinetics for the degradation of CXCR4 and SDF-1, concurrent with B5-fold increases in elastase activity. Our results therefore also support a major role for elastase in HPC mobilization (Gazitt et al, unpublished) .
A possible role for MMP9 in HPC mobilization is intriguing since it has been reported that MMP9 is most likely involved in IL-8-induced HPC mobilization in mice and monkeys. [91] [92] [93] In these models, a thousand-fold increase in MMP9 activity was induced by a single injection of IL-8, concomitant with B100-fold increases in circulating HPC, observed within 1 h of treatment. 91, 92 Furthermore, IL-8-induced HPC mobilization could be blocked by pretreatment with anti-MMP9 antibodies. 93 Thus, at this point, IL-8-induced mobilization of HPC seems mechanistically distinct from G-CSF-or GM-CSF-induced mobilization of HPC, both in the kinetics and in the proteases involved in the process. Based on a wide consensus in the field, it is not likely that the IL-8 and MM9 pathway plays a physiological role in HPC mobilization. A summary cartoon of the changes in adhesion molecules and chemokines during CD34 þ cell mobilization by chemotherapy, G-CSF and/or GM-CSF is presented in Figures 1 and 2 .
Crosstalk between chemokines, adhesion molecules, hematopoietic growth factors and chemokine receptors
High expression of adhesion molecules and CXCR4 on CD34 þ cells and high levels of SDF-1 are required for migration and engraftment of CD34 þ cells. 48, 50, 52, 86, 87 However, at the time of infusion, the expression of adhesion molecules and CXCR4 on CD34 þ cells in apheresis collections of mobilized patients Figure 1 Reciprocal changes in the expression of adhesion molecules and SDF-1/CXCR4 signaling in mobilization and homing of CD34 þ HPC. Mobilization and homing are mirror images and opposite processes involving the same molecules in both the processes but in opposite directions. The key players are the CXCR4/SDF-1 axis and its disruption by proteases leading to the release of HPC from the BM to the peripheral blood.
Hematopoietic stem cell and cancer cell mobilization Y Gazitt is relatively low. 39, 40 Therefore, there must be an in vivo process that allows for re-expression of adhesion molecules and CXCR4. Indeed, recent findings indicate that SDF-1 can upregulate the expression of adhesion molecules 48, [62] [63] [64] 70 and that cytokines such as flt3-L, SCF, IL-3 and IL-6 upregulate the expression of CXCR4 in vitro and in vivo. 73, [94] [95] [96] [97] [98] [99] On the other hand, cytokines such as G-CSF and SCF can directly upregulate the expression of VLA-4 and VLA-5. [94] [95] [96] Hence, it is reasonable to assume that endogenous cytokines or exogenously administered growth factors following high-dose chemotherapy could facilitate the process of engraftment. Further support for this hypothesis comes from recent reports demonstrating a rapid surface reexpression of CXCR4 in vitro and in vivo in mice following treatment with cytokines. 73, 100 A schematic summary of the crosstalk between cytokines, chemokines and adhesion molecules is presented in Figure 3 .
Mobilization of tumor cells
Comobilization of tumor cells, including clonogenic tumor cells (HCC), occurs following chemotherapy or growth factor administration and has been well documented for hematological malignancies, including lymphoma, multiple myeloma and solid tumors. [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] Numerous methods have been developed to purge tumor cells from the graft of autotransplant donors.
However, in several large multicenter studies, it has been shown that purging of tumor cells from the graft does not result in increased survival compared to nonpurged grafts. 106, 107, 111, 112 Therefore, there is consensus that tumor cells in the host constitute the main source for relapse.
Adhesion molecules in the mobilization of tumor cells
Recent studies revealed that adhesion molecules, such as VLA-4, VLA-5, and H-CAM, and SDF-1/CXCR4 signaling are also involved in homing and release of cancer cells in a similar way as for HPC. [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] Involvement of VLA-4 and VLA-5 in adhesion of myeloma cells to stromal cells and the resulting drug resistance has been extensively studied. [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] H-CAM (CD44) constitutes yet another superfamily of adhesion molecules by which cancer cells of various types interact with hyaluronic acid on the surface of stromal cells. [117] [118] [119] [120] [121] [122] [123] [124] This interaction has been studied extensively in myeloma cells. Isoforms v9 and v10 have been shown to play an important role in the interaction between myeloma cells and stromal cells. This interaction is also common in solid tumors. [118] [119] [120] [121] [122] [123] [124] CXCR4/SDF-1 signaling in the mobilization of cancer cells SDF-1/CXCR4 signaling is active in all cancer cells studied, [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] including solid tumors such as rhabdomyosarcoma, 125 prostate cancer, 126 kidney 127 and melanoma. 128 Similarly, signaling by SDF-1/CXCR4 is active in all hematological malignancies studied, including chronic lymphocytic leukemia (CLL), [129] [130] [131] NHL, 132,133 chronic myelogenous leukemia, 134 acute leukemias [135] [136] [137] and multiple myeloma. 138, 139 Further support for the critical role of the SDF-1/CXCR4 signaling in the survival, homing and mobilization of cancer cells was obtained from several recent studies demonstrating that blocking of CXCR4 by specific antibodies or by CXCR4-blocking peptides such as AMD3100 results in mobilization of tumor cells and blocking of human lymphoma and leukemia cell growth in xenograft mouse models. [140] [141] [142] [143] In this regard, we studied the role of adhesion molecules and chemokines in human myeloma cells and reported that MIP-1a upregulates the expression of VLA-5 in vitro and in vivo in a xenograft mouse model. 116 Blocking of MIP-1a resulted in a decreased survival of myeloma cells. We also observed decreased bone disease in mice engrafted with ARH-77 myeloma cells transfected with antisense MIP-1a-expressing vector. 116 More recently, we studied the involvement of adhesion molecules and SDF-1/CXCR4 signaling in the mobilization of myeloma cells, and plasma levels of SDF-1. We measured the expression of VLA-4, VLA-5 and CXCR4 on CD38 þ CD138 þ myeloma cells in the blood of mobilized myeloma patients compared to steady-state BM cells. We observed a significant decrease in the expression of VLA-4 and CXCR4 on mobilized myeloma cells, compared to steady-state BM. These decreases correlated with decreases in plasma SDF-1. Myeloma cells purified from the apheresis collections had poor adhesion to autologous stroma and poor trans-stromal migration compared to BM-derived myeloma cells. 117 These results suggest that mobilization of myeloma cells requires downregulation of VLA-4 and disruption of SDF-1/CXCR4 signaling. By contrast, homing of myeloma cells appears to require upregulation and activation of adhesion molecules and active signaling through the SDF-1/ Figure 2 Schematic representation of the sequence of events in chemotherapy and/or growth factor-induced mobilization of HPC. Mobilization by CXCR4 blocker takes 6-16 h compared to X5 days for growth factors and does not involve neutrophilia.
Figure 3
Crosstalk between chemokines, adhesion molecules, hematopoietic growth factors and chemokine receptors. SDF-1 upregulates adhesion molecules and downregulates its own receptor, CXCR4. On the other hand, adhesion molecules can be upregulated by chemokines as well as by hematopoietic growth factors such as G-CSF or CSF. The inter-regulation between chemokines and other hematopoietic growth factors is poorly understood at this juncture.
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Crosstalk between chemokines, chemokine receptors, adhesion molecules and hematopoietic growth factors
Crosstalk between chemokines, growth factors and adhesion molecules occurs in cancer cells as was shown above for HPC. [116] [117] [118] 125, 136 However, it is not yet fully studied. In addition, it has been reported that SDF-1 modulates VLA-4 and VCAM, and thus affects adhesion of myeloma cells to stroma and to fibronectin. 117, 118, 124 In other studies, SDF-1 was capable of affecting the migration and adhesion of leukemic cells through upregulation of integrins. 136 Therefore, although sparse information is currently available regarding crosstalk between chemokines, chemokine receptors, adhesion molecules and hematopoietic growth factors in cancer cell homing and mobilization, it is reasonable to predict that such crosstalk indeed exists.
Based on the plethora of publications in this field, it is concluded that mobilization and homing of tumor cells follow the same requirement as outlined above for HPC, and that mobilization and homing of HPC and tumor cells are parallel processes occurring concurrently in the same patient during the course of administration of anticancer drugs.
Proteases involved in mobilization of HCC
Matrix metalloproteinases such as MMP2 and MMP9 are the likely proteases involved in mobilization and metastasis and not neutrophil elastase. [144] [145] [146] [147] [148] [149] [150] [151] A summary of the changes in adhesion molecules and chemokines during mobilization and homing of HCC is presented in Figures 4 and 5 .
The conundrum
Mobilization and homing of HPC and HCC are parallel processes and occur concurrently in the same patient during the course of treatment with anticancer drugs and/or growth factors. It is proposed that following each cycle of treatment, cancer cells lose adhesion molecules and CXCR4 signaling. Surviving cancer cells are released from the primary or secondary sites (eg, BM, lymph node) to the circulation, where they circulate until re-expression of adhesion molecules and CXCR4 receptors occurs. Subsequently, HCC migrate and home to stromal cells in the marrow or to the extracellular matrix in distal organs via SDF-1/CXCR4 and possibly by other chemokines. HCC utilize growth factors secreted by resident cells in the new microenvironment (eg, stromal cells), proliferate and vascularize. Subsequent rounds of chemotherapy result in repeated homing and mobilization of HCC with an overall increase in drug resistance due to two different mechanisms: 'intrinsic' and 'extrinsic' drug resistance. Intrinsic drug resistance results from random mutations and selection for cells with decreased expression of tumor suppressor genes or increase expression of survival genes (eg, growth factors, oncogenes, Bcl-2 family of proteins, etc). Extrinsic drug resistance results from protection of displaced tumor cells by growth factors available to them in their new microenvironment. This process of increased drug resistance is amplified in each round of chemotherapy until cancer relapses and clinical disease progression occurs. Escalating the dose of chemotherapy does not result in tumor ablation due to the forced selection of drugresistant cells.
Numerous examples of the role of the microenvironment in the survival and drug resistance of tumor cells have been reported in hematological malignancies 124, [152] [153] [154] [155] [156] [157] [158] [159] [160] and new strategies for drug development that consider tumor cells in their microenvironment are being developed for various types of cancer. 160, 161 Growth factors and chemokines are survival and proliferation signals for myeloma, leukemia and lymphoma cells. 138, 139, [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] The most studied models are in multiple myeloma. In myeloma, the contributions of stromal IL-6, SDF-1/ CXCR4, MIP-1a and adhesion molecules have been studied extensively in the context of drug resistance and bone disease involving autocrine/paracrine loops between myeloma cells, stromal cells and osteoclasts resulting with drug resistance, tumor progression and bone destruction. 116, 124, [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] A very recent work by Dalton's group and a review article describe in detail the role of the microenvironment, extracellular matrix Reciprocal changes in the expression of adhesion molecules and SDF-1/CXCR4 signaling in the mobilization and homing of myeloma cells. Mobilization and homing are mirror images and opposite processes involving the same molecules in both the processes but in opposite directions.
Figure 5
Schematic representation of the sequence of events in chemotherapy or colony stimulating factor-induced mobilization of hematopoietic cancer cells. A similarity exists between CD34 þ HPC mobilization and cancer cell mobilization, except for the types of proteases involved.
Hematopoietic stem cell and cancer cell mobilization Y Gazitt (ECM) proteins and cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma. 159, 160 Hence, multiple rounds of chemotherapy and/or growth factors accelerate the process of drug resistance and tumor progression, and escalating doses of chemotherapy are not efficacious since they result in increased myelosuppression and toxicity to normal tissues, whereas cancer cells become increasingly drug resistant, intrinsically and extrinsically. Similarly, 'spontaneous metastasis' in chemotherapy naïve cancer patients could result from inflammatory processes in which cancer cells are mobilized in the same way as cytotoxic neutrophils, T cells, macrophages and dendritic cells are mobilized to the inflammation site utilizing the same cytokines and adhesion molecules. According to the proposed model, treatment with chemotherapy and/or growth factors is an extreme case of inflammation. A proposed schematic model for this 'vicious cycle' is shown below. This model is proposed for hematological malignancies, and further studies are needed to prove its general applicability to other types of cancer (Figure 6 ).
Future directions
Chemotherapy is a double-edged sword. Fortunately, the phenomenon of drug/growth factors-induced mobilization of cancer cells could be used to eradicate effectively circulating cancer cells in the blood, before homing takes place and drug resistance evolves. This can be accomplished by concurrent treatment of cancer patients with chemotherapy and lineage-specific antibodies such as Campath-1H (anti-CD52) for CLL, Gemzutumab (anti-CD33) for acute myelogenous leukemias (AML) and Rituximab (anti-CD20) for B-cell malignancies. [162] [163] [164] In the proposed model, chemotherapy is useful in the mobilization of tumor cell, whereas the killing is done mostly by lineage-specific antibodies, in the blood where cancer cells are more accessible to antibodies and more sensitive to cytotoxic drugs. In the current mobilization protocol, emphasis is placed on the collection of sufficient amounts of HPC. Mobilization of tumor cells is a necessary evil and relatively low numbers of HCC are mobilized due to the fact that chemotherapy (eg, cyclophosphamide) is given only once followed by several days of growth factor alone. In contrast, in the proposed model, chemotherapy and antilineage antibodies are given repeatedly (eg, every week) as a treatment protocol and not as a mobilization protocol. Thus, in the proposed model, repeated purging of tumor cells is achieved in vivo during the course of a long treatment (eg, 2-3 months). Furthermore, for cancer cell mobilization, much lower doses of chemotherapy could be used. Hence, it is proposed that following induction chemotherapy (ie, VAD for multiple myeloma, or CHOP for lymphoma), consolidation of remission could be achieved by continuous adjuvant treatment with antilineage-specific antibodies and lower doses of chemotherapy (ie, low-dose ESHAP plus low doses of Rituximab for lymphoma patients). This approach is expected to maintain patients in complete remission by reducing the process of spreading of the disease to new sites and development of drug resistance. Also, continuous adjuvant treatment with antilineage-specific antibodies should work effectively to maintain patients in complete remission by reducing the process of spreading to new sites. Indeed, recent reports indicate that treatment of CLL patients with Campath-1H is effective in reducing tumor burden 165, 166 and more so when used concurrently with fludarabine. 167, 168 However, in the high doses currently used, Campath-1H is toxic as single agent or in combination with chemotherapy in CLL patients and particularly in NHL patients. [169] [170] [171] It is important to stress that in the proposed model of concurrent chemotherapy and antibody therapy, relatively low doses of chemotherapy are sufficient to mobilize tumor cells to the peripheral blood, much lower than the currently used doses for concurrent chemotherapy and antilineage-specific antibody. Therefore, it is anticipated that the observed immunosuppression and hematological toxicities will be markedly reduced with an increase in the therapeutic index.
Rituximab is widely used in the treatment of patients with NHL, alone or in combination with chemotherapy. Recent reports indicate that treatment of NHL patients with Rituximab following high-dose chemotherapy (HDCT) for PBSC collection results in an in vivo purging of lymphoma cells. [172] [173] [174] [175] [176] Unlike Campath-1H, Rituximab is much more tolerable both as a single agent and in combination with chemotherapy. 174, 175 Furthermore, in recent randomized trials, concurrent treatment of NHL patients with Rituximab and HDCT was more effective than sequential treatment with chemotherapy followed by Rituximab. [177] [178] [179] Gemtuzumab is being used in the treatment of AML patients. 180, 181 Recent studies, however, reported treatment-related toxicities for Gemtuzumab alone or in combination with chemotherapy. [182] [183] [184] [185] [186] Hence, Campath-1H and Gemtuzumab appear to be more toxic than Rituximab and might not be efficacious under currently used treatment protocols. However, they might have higher therapeutic index under the proposed concurrent therapy model, in which lower doses of both, chemotherapy and antilineage-specific antibody, are sufficient to obtain responses. Hematopoietic stem cell and cancer cell mobilization Y Gazitt
